There is a lot of room for domestic alternatives to biological front-ends, and many pharmaceutical machine companies have frequently received investment and financing

Recently, after the WuXi Biologics incident, the key core technologies were limited by human troubles, which caused heated discussions in the industry
.
In this context, the concept stocks upstream of biopharmaceuticals have also continued to gain the attention of the capital market
.
For example, a research report recently disclosed by Chutian Technology showed that in the communication session, the organization paid attention to the progress of the company's disposable products, the current technical level of stainless steel bioreactors, and the future planning in the bioengineering sector
.
Pharmaceutical equipment (Photo source: Pharmaceutical Network) It is understood that the upstream industrial chain of biopharmaceuticals mainly includes raw materials, consumables and instruments/equipment
.
Among them, reagents and consumables have basically been localized in China, while disposable biological reaction equipment and key reagent consumables in the high-end field still need to rely on imports due to their high technical content and difficult research and development
.
Due to the huge domestic alternative space and market potential of biological front-end equipment and consumables, in recent years, many pharmaceutical equipment companies have accelerated their deployment in the upstream field of biopharmaceuticals
.
And capital is increasingly favoring these fields, and many pharmaceutical machine companies have successively obtained investment and financing
.
For example, in the primary market, Duoning Bio, a platform supplier in the field of serum-free culture medium, disposable products and bioreactors in the domestic biopharmaceutical industry, has been working hard to evolve into a one-stop supply platform since 2019
.
In 2021, Duoning Bio received hundreds of millions of B rounds of financing, C rounds of financing and hundreds of millions of dollars in B+ rounds of financing in April, November and December, respectively
.
Among them, in November 2021, the company announced the completion of the C round of financing.
The funds will be used for the company's industrial chain layout to accelerate the construction of the company's localized one-stop supply platform.
This round of financing includes Sequoia, Qingchi, Huitianfu, etc.
large investment institutions
.
In December of the same year, the B+ round of financing of hundreds of millions of dollars was completed, and 11 investment institutions included Legend Jianan, Shanghai Lianxin, and Hillhouse Qirui
.
In the secondary market, the stock prices of domestic pharmaceutical machine giants Tofflon and Chutian Technology have soared by 558.
09% and 210.
15% respectively since 2020
.
The two companies have also accelerated their deployment in the field of biopharmaceutical equipment since 2020
.
Among them, Chutian Technology has made rapid progress in the front-end process and equipment layout of biopharmaceuticals.
In 2021, Chutian Usite and Chutian Microspheres have been established successively, which are respectively used for related single-use process equipment, consumables and products in the field of biopharmaceuticals.
Production and sales of software, and development and production of biopharmaceutical process products such as disposable bioreactors, liquid dispensing bags, liquid storage bags and their membrane materials
.
The company said on the interactive platform that the Shanghai factory is currently under construction and is expected to be put into production within this year
.
In addition, at the end of February this year, Chutian Technology announced the establishment of a holding company, Chutiansiweikang Gene, which is committed to promoting the layout in the field of biotechnology
.
Tofflon recently launched a fixed increase fund-raising action since its listing.
The company plans to raise no more than 3.
2 billion yuan to expand production capacity to meet the rapidly growing downstream market demand
.
It is reported that the funds raised will be used for the construction of the biopharmaceutical equipment industry trial production center, the Jiangsu biomedical equipment industrialization base, and the Hangzhou life science industrialization base
.
Among them, the Hangzhou life science industrialization base project plans to invest 1.
25 billion yuan, accounting for 39.
1%
.
The project will mainly provide equipment and instruments, culture media, packaging materials and liquid separation products that meet GMP requirements for new biological drugs of cell and gene therapy
.
From the perspective of the layout of these pharmaceutical machine companies, the pace of domestic substitution of biological front-end equipment is expected to accelerate in the future
.
The industry believes that, compared with the stainless steel system, the disposable system has outstanding advantages, and there is also a large space for replacement in the future
.
A research report released by China Merchants Securities shows that at present, domestic disposable technology suppliers are mainly divided into three categories: stainless steel equipment manufacturers, disposable technology, material and component suppliers.
Representative companies include Tofflon, Chutian Technology, Jinyi Shengshi, Morison International, Duoning Bio, Lechun Bio,
etc.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.